AlloCure's most advanced program, AC607, is a novel biologic therapy under development for acute kidney injury (AKI) with potential applications in other grievous illnesses. AC607 is composed of adult bone marrow-derived mesenchymal stem cells (MSC) that are expanded by a mature and proprietary, state-of-the art manufacturing process. In the setting of AKI, AC607 homes to the injured kidney where it mediates an anti-inflammatory, organ repair process via the secretion of multiple beneficial paracrine factors. Importantly, AC607 avoids recognition by the immune system, enabling its use in an "off-the-shelf" paradigm without the need for blood or tissue typing.

AlloCure has completed a phase 1 clinical trial of AC607 conducted in cardiac surgery subjects at high risk for the development of AKI. Study results demonstrated that the adverse event profile observed in AC607-treated subjects was consistent with that expected for this subject population and no serious adverse events were attributed to AC607 therapy. Furthermore, treated subjects experienced a lower incidence of AKI, reduced length of hospital stay, and reduced hospital readmission rates compared to a cohort of historical controls.

Building on the success of the phase 1 clinical trial, AlloCure has initiated ACT-AKI, a randomized, multicenter, double-blind, placebo-controlled phase 2 clinical trial in cardiac surgery subjects with post-operative AKI.

Currently, there are no effective treatment options for patients with AKI. These trials represent the first application of a stem cell therapy to alter the course of this potentially life threatening condition.

AlloCure is a privately held company focused on the treatment of kidney disease. AlloCure's investors include SV Life Sciences, Novo Ventures and Lundbeckfond Ventures. The company's headquarters are located in Burlington, MA, with an additional location in Salt Lake City, UT.